콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

198M-1

Sigma-Aldrich

CD123 (6H6) Mouse Monoclonal Antibody

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
NACRES:
NA.41

생물학적 소스

mouse

Quality Level

100
500

결합

unconjugated

항체 형태

culture supernatant

항체 생산 유형

primary antibodies

클론

6H6, monoclonal

설명

For In Vitro Diagnostic Use in Select Regions (See Chart)

형태

buffered aqueous solution

종 반응성

human

포장

vial of 0.1 mL concentrate (198M-14)
vial of 0.5 mL concentrate (198M-15)
bottle of 1.0 mL predilute (198M-17)
vial of 1.0 mL concentrate (198M-16)
bottle of 7.0 mL predilute (198M-18)

제조업체/상표

Cell Marque

기술

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

동형

IgG1κ

제어

blastic plasmacytoid dendritic cell neoplasm

배송 상태

wet ice

저장 온도

2-8°C

시각화

cytoplasmic

일반 설명

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma, is a malignant neoplasm composed of immature hematopoietic precursors of plasmacytoid dendritic cells. The most frequent manifestation is a skin lesion, bone marrow involvement, and regional lymphadenopathy. Myeloid leukemia cutis (LC), myeloid sarcoma, and large aggressive B cell lymphomas should be differentiated from BPDCN. Recently, it has been reported that these entities can be distinguished by using immunohistochemistry (IHC) in paraffin-embedded tissue sections. In this study, 23 myeloid LC and 12 BPDCN cases were evaluated using a panel of antibodies against CD123, TCL1, CD4, CD56, MPO and CD33; with results as follows: anti-CD123 stained 4 cases (17%) of myeloid LC and 10 cases (83%) of BPDCN; anti-TCL-1 stained 2 cases (9%) of myeloid LC and 9 (82%) of 11 cases of BPDCN; anti-CD4 stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; anti-CD56 stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; anti-myeloperoxidase stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN. Anti-CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. The results indicated that a panel that includes antibodies against CD4, CD56, CD123, and TCL-1 can appropriately distinguish between myeloid LC and BPDCN.
CD123 IHC expression has been studied in 157 acute myeloid leukemia (AML) bone marrow biopsies and/or marrow particle preparations, and correlated with the morphologic, immunophenotypic, and cytogenetic features and with the presence of FLT3-ITD and NPM1 mutations. CD123 IHC expression has been seen in 40% of AML, across a wide spectrum of 2008 World Health Organization subtypes and was most frequent within the intermediate risk group. Compared with CD123 IHC negative AML, CD123 IHC positive AML demonstrated higher marrow blast percentages (median 69%), monocytic differentiation (33/63 cases), and CD34 negativity (29/63 cases). 83% (25/30) FLT3-ITD-mutated AML were CD123+ and 62% (18/29) NPM1-mutated cases were CD123 IHC+ (P=0.0052). CD123 IHC+AML presents with characteristic pathologic features, some of which may be related to underlying FLT3-ITD and/or NPM1 mutations.

품질


IVD

IVD

IVD

RUO

결합

CD123 Positive Control Slides, Product No. 198S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

물리적 형태

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

제조 메모

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

기타 정보

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

법적 정보

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)
Marian Rollins-Raval et al.
Applied immunohistochemistry & molecular morphology : AIMM, 21(3), 212-217 (2012-08-24)
FLT3-ITD and NPM1 mutation testing in acute myeloid leukemia (AML) plays an important role in prognostic risk stratification, especially within the intermediate cytogenetic risk group. Molecular studies require adequate fresh material and are typically performed on a dedicated aspirate specimen
Facchetti F, et al.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 145-147 (2008)
Danielle M P Cronin et al.
American journal of clinical pathology, 137(3), 367-376 (2012-02-18)
Myeloid leukemia cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.